Compare SEZL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SEZL | DNTH |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Financial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.5B |
| IPO Year | 2023 | 2018 |
| Metric | SEZL | DNTH |
|---|---|---|
| Price | $153.89 | $103.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $109.33 | ★ $121.00 |
| AVG Volume (30 Days) | 600.7K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $450,279,000.00 | $2,036,000.00 |
| Revenue This Year | $30.30 | N/A |
| Revenue Next Year | $24.79 | $29.48 |
| P/E Ratio | $108.17 | ★ N/A |
| Revenue Growth | ★ 66.08 | N/A |
| 52 Week Low | $49.50 | $18.08 |
| 52 Week High | $195.71 | $107.99 |
| Indicator | SEZL | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 58.23 |
| Support Level | $60.73 | $89.21 |
| Resistance Level | $190.36 | N/A |
| Average True Range (ATR) | 12.49 | 5.76 |
| MACD | -4.44 | 0.25 |
| Stochastic Oscillator | 1.30 | 72.73 |
Sezzle Inc is a financing institution that offers technology-driven payment platform. The Sezzle Platform offers a payments solution for consumers in the United States and Canada that has the ability to instantly extend credit at the point-of-sale, allowing consumers to purchase and receive merchandise while paying in installments over time. Consumers pay a portion of the purchase price at the point-of-sale as a down payment, and then pay off the remaining amount over time through scheduled payments. It also offer the ability to pay-in-full using the Sezzle Platform. Its operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.